Precipio, Inc. PRPO 深 沪
已收盘 07-02 16:00:00 美东时间
25.26
+0.330
+1.32%
华盛通- 最 高25.365
- 今 开25.2925
- 成交量 6893股
- 最 低 22.76
- 昨 收 24.93
- 总市值 4514.90万
- 52周最高 33.63
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 13.02
- 委 比 98.67%
- 总股本 178.74万
- 历史最高 8448.00
- 量 比 0.32
- 振 幅 10.45%
- 历史最低 3.90
- 每 手 1
- 风险率 4.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, is urging shareholders to instruct their brokers to vote their shares by June 14, 2026, at 11:59 p.m. Eastern Time, to ensure a quorum for its Annual Meeting on June 15, 2026. Currently, approximately 42% of shares have been voted, and at least 50% are needed to hold the meeting. If insufficient votes are received, the meeting may need to be adjourned and reconvened, resulting...
06-12 17:00
Precipio to Present at the Planet MicroCap Las Vegas
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026, at 9:00 AM local time (12:00 PM EST) at the Bellagio Resort & Hotel. CEO Ilan Danieli and COO Zaki Sabet will host the presentation and answer questions. Precipio aims to expand its shareholder base and raise awareness rather than seek capital. The live presentation and registration details are availab...
06-11 21:00
Precipio Q1 EPS $(0.81) Down From $(0.59) YoY, Sales $6.711M Up From $4.929M YoY
Precipio (NASDAQ:PRPO) reported quarterly losses of $(0.81) per share. This is a 37.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported $6.711 million in sales this
05-15 05:03
Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported first-quarter 2026 revenue of $6.71M, flat from Q4-2025 but up 36% year-over-year. Product revenue declined temporarily due to delayed shipments. Adjusted EBITDA was $(0.16)M, impacted by CMS cuts, product shipment delays, and hiring costs. Cash flow was positive $60K. CEO Ilan Danieli noted underlying growth, particularly in the expanding product pipeline, expecting second-half growth.
05-14 21:00
Management team’s 2025 market-based Options have vested
Precipio, Inc. announced that its 2025 employee stock options granted to management vested due to a 400% increase in its share price from $6.06 to a 10-day VWAP of $30.30. The Company replaced standard time-based vesting with a market-based structure, where options vest upon reaching a specified share price. CEO Ilan Danieli highlighted this as aligning management incentives with shareholders. In 2026, management agreed to a similar structure wit...
05-13 21:00
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. (NASDAQ: PRPO) will host its Q1-2026 shareholder update call on May 18, 2026, at 5:00 PM ET. The call will feature remarks on the company’s core businesses and include a live Q&A session. This is the first time Precipio will incorporate a dedicated moderated Q&A into its quarterly update. Investors can submit questions in advance to investors@precipiodx.com or join the call by dialing 646.307.1865. A replay will be available on Pre...
05-06 21:00
Earnings Scheduled For April 2, 2026
Companies Reporting Before The Bell • Pharvaris (NASDAQ:PHVS) is estimated to r...
04-02 19:11
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Precipio, Inc., a specialty cancer diagnostics company, will host a conference call on April 2nd, 2026, at 5:00 PM ET to discuss Q4 and year-end 2025 updates. Participants can join by dialing 646.307.1865 and requesting the Precipio Inc. conference call. Pre-submitted questions can be emailed to investors@precipiodx.com. A replay will be available via Precipio's Investor page within 24 hours. Precipio focuses on improving cancer diagnostics to re...
03-12 21:00
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
Precipio, Inc. has launched the first and only BCR::ABL1 assay that simultaneously detects and quantifies all four clinically relevant isoforms, setting a new standard for monitoring Chronic Myeloid Leukemia (CML). Unlike existing assays, Precipio’s Bloodhound BCR::ABL1 assay provides full quantification of all four isoforms, enabling comprehensive disease monitoring and early detection of relapse. With high sensitivity, it detects changes as low...
03-10 13:00
Precipio Q4 2025 Preliminary Revenue $6.7M, An Increase Of 23% From $5.4M YoY
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025.Below are some of the key financial performance metrics
02-25 22:33
